World’s First AutoStore Solution With Frozen Food Zone to Be Installed by StrongPoint
StrongPoint ASA (ticker: STRO), a leading grocery retail technology provider, has been chosen to design and install the world’s first AutoStore solution purpose built for food management with three temperature zones: ambient, chilled and now, frozen. StrongPoint is AutoStore’s first and only grocery-focused distribution partner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221023005106/en/
(Photo: Business Wire)
AutoStore, the robot technology company that invented, and continues to pioneer, Cube Storage Automation, has recently developed a unique solution to automate the storage and retrieval of frozen items. Previously, AutoStore’s solutions have only covered two temperature zones, chilled and ambient. Most grocery retailers have been using manual picking for frozen items when automating their e-grocery fulfilment services, an essential product segment for grocery retailers.
StrongPoint is a grocery technology company with 35 years’ experience in food management and provides end-to-end e-commerce fulfilment solutions to many leading grocery retailers in Europe. StrongPoint will design and install the AutoStore solution for the Norwegian food distribution company, DLVRY, in a facility based in Sveio, Norway. In addition to increased efficiency, by adding frozen items into the AutoStore grid, substantial energy savings can be made. In this installation, it is expected to result in approximately 30% reduction in energy costs.
“This is a great day for grocery retailers and food management companies looking at automation to boost efficiency as they can now automate all three temperature zones. We are proud to have the honour of installing a world first for AutoStore and look forward to leveraging our 35+ years’ experience in food management and grocery retail to create the world’s first and best fully automated solution purpose built for groceries,” said StrongPoint CEO, Jacob Tveraabak.
“Food management is so different to any other retail segment we wanted to ensure we had access to a team that really understood our unique challenges which is why we decided to work with StrongPoint. We are especially proud we are the world’s first company to use AutoStore’s frozen-food capabilities as it means we can achieve much higher efficiency rates by automating what was until now, not possible,” said Jan Frode Johansen, Co-Founder and CEO of DLVRY.
Notes to editors:
- StrongPoint provides an end-to-end grocery e-commerce solution including automation, in-store picking, dark store picking, home delivery, click and collect grocery lockers, in-store pickup and drive-thru
- The multi-temperature AutoStore grid includes three temperature zones: ambient, chilled and frozen.
- The AutoStore grid can be installed in multiple discrete temperature zones ranging down to sub-zero temperature (-25 °C / -13 °F) and allows both fresh & frozen goods to be picked from the chilled-temperature zone (2 °C / 35.6 °F).
About StrongPoint
About StrongPoint StrongPoint is a grocery retail technology company that provides solutions to make shops smarter, shopping experiences better and online grocery shopping more efficient. With over 500 employees in Norway, Sweden, the Baltics, Spain, the UK and Ireland and together with a wide partner network, StrongPoint supports grocery and retail businesses in more than 20 countries. StrongPoint provides in-store and e-commerce solutions and is AutoStore’s first and only grocery-focused distribution partner. StrongPoint is headquartered in Norway and is listed on the Oslo Stock Exchange with a revenue of approx 1bn NOK [ticker: STRO]. Learn more at www.strongpoint.com
About AutoStore
AutoStore, founded in 1996, is a robot technology company that invented, and continues to pioneer, Cube Storage Automation - the densest product/inventory storage solution in existence. The company's focus is to marry software and hardware with human abilities to create the future of warehousing. AutoStore is global, with more than 950 systems installed in +45 countries over a wide range of industries. All sales are designed, installed, and serviced by a network of qualified system integrators - which AutoStore calls 'partners'. The company headquarters is in Nedre Vats, Norway, with offices in Oslo (Norway), the U.S., UK, Germany, France, Spain, Italy, Austria, South Korea, Japan, and Singapore. Learn more at www.autostoresystem.com
About DLVRY
DLVRY is a Norwegian foodservice company focused on the local part of the market, where the company can leverage its strengths in logistics, flexibility, and high service level to local clients. The company was created 2021 by combining five regional players that service local and regional HORECA clients in Norway. Headquartered in Oslo, Norway, and with local branches all over Norway.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221023005106/en/
Contact information
Jacob Tveraabak
CEO StrongPoint ASA
Tel: +47 908 21 370
jacob.tveraabak@strongpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom